Loading data
GENINYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 669.49 m USD | 510.89 m USD | 412.98 m USD | 341.03 m USD | 262.74 m USD |
| Cost of revenue | 515.65 m USD | 382.19 m USD | 343.97 m USD | 338.17 m USD | 476.17 m USD |
| Gross profit | 153.84 m USD | 128.71 m USD | 69.01 m USD | 2.86 m USD | -213.43 m USD |
| Research and development expense | 31.09 m USD | 24.58 m USD | 26.07 m USD | 29.89 m USD | 26.51 m USD |
| Operating profit | -151.33 m USD | -58.54 m USD | -74.16 m USD | -182.87 m USD | -573.29 m USD |
| Profit before tax | -117.73 m USD | -66.26 m USD | -83.3 m USD | -183.28 m USD | -604.45 m USD |
| Income tax expense | -2.5 m USD | 509 k USD | 5.34 m USD | 1.71 m USD | -11.7 m USD |
| Net income (reported basis) | -111.58 m USD | -63.04 m USD | -85.53 m USD | -181.64 m USD | -592.75 m USD |
| Net income attributable to common shareholders | — | — | -85.53 m USD | -181.64 m USD | -604.08 m USD |
| Basic earnings per share | -0.44 USD/share | -0.27 USD/share | -0.38 USD/share | -0.85 USD/share | -3.79 USD/share |
| Diluted earnings per share | -0.44 USD/share | -0.27 USD/share | -0.38 USD/share | -0.85 USD/share | -3.79 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.